Multiple Sclerosis News Today Forums Forums Trials and Research Small Trial of 24 Offers a Methodology for Tackling MS via Attacking EBV Virus,

Tagged: , ,

  • Small Trial of 24 Offers a Methodology for Tackling MS via Attacking EBV Virus,

    Posted by John Connor on April 22, 2022 at 1:17 pm

    As usual, this story would be years off and hasn’t even been peer-reviewed yet. I’m reporting it cos I’ve spent 2 hours researching it – so there.

    There’s been oodles of science re EBCV & MS – we currently carry 82 stories about this on our home site.

    ‘A phase 1 clinical trial by the California-based immunotherapy company Atara Biotherapeutics confirms latent Epstein-Barr (EBV) infections are viable targets for treating MS in at least some patients, reinforcing a curious link between the virus and a deadly illness that affects millions around the world.

    Out of the trial’s 24 volunteers, 20 showed signs of either improvement or at least a halt in their health’s steady decline. Importantly, there were no signs of serious side effects.

    Any thoughts on this study?

    John Connor replied 2 years, 1 month ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.